Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia

Vaptans may correct hyponatraemia and mobilise ascites through an increased excretion of water. The effect on clinical outcomes is debated.

[1]  F. Czerwiec,et al.  Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. , 2012, Journal of hepatology.

[2]  A. Gerbes,et al.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity , 2011, Gut.

[3]  V. Arroyo,et al.  Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[4]  P. Gow,et al.  Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. , 2010, Journal of hepatology.

[5]  T. Berl,et al.  Oral tolvaptan is safe and effective in chronic hyponatremia. , 2010, Journal of the American Society of Nephrology : JASN.

[6]  R. Brůha,et al.  Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study , 2010, Alimentary pharmacology & therapeutics.

[7]  A. Gerbes,et al.  857 SATAVAPTAN EFFICACY AND SAFETY IN RECURRENT ASCITES WITHOUT CONCOMITANT DIURETICS: THE SPARE-2 STUDY , 2010 .

[8]  F. Nevens,et al.  Double-blind, placebo-controlled study of satavaptan in the management of recurrent ascites: the spare-1 study , 2009 .

[9]  B. Gómez-Anson,et al.  Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis , 2009, The American Journal of Gastroenterology.

[10]  F. Wong,et al.  102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY , 2009 .

[11]  F. Wong,et al.  Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial , 2008, Hepatology.

[12]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.

[13]  F. Wong,et al.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. , 2007, Gastroenterology.

[14]  F. Wong,et al.  [90] LONG-TERM IMPROVEMENT OF SERUM SODIUM BY THE V-RECEPTOR ANTAGONIST SATAVAPTAN IN PATIENTS WITH CIRRHOSIS AND HYPONATRAEMIA , 2007 .

[15]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[16]  F. Wong,et al.  732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia , 2006 .

[17]  A. Gerbes,et al.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. , 2003, Gastroenterology.

[18]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[19]  B D Ross,et al.  Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. , 1995, The Journal of clinical investigation.

[20]  Vicente Arroyo,et al.  Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis , 1988, Hepatology.

[21]  G. D’Amico,et al.  Survival and prognostic indicators in compensated and decompensated cirrhosis , 1986, Digestive Diseases and Sciences.

[22]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.